CoChat

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

Open access
Hassan, Burhan, Akcakanat, Argun, Sangai, Takafumi, Evans, Kurt W., Adkins, Farrell, Eterovic, Agda Karina, Zhao, Hao, Chen, Ken, Chen, Huiqin, Do, Kim-Anh, Xie, Shelly M., Holder, Ashley M., Naing, Aung, Mills, Gordon B., Meric-Bernstam, Funda · 2014 · Oncotarget
Cited by 61

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

// Burhan Hassan 1 , Argun Akcakanat 2 , Takafumi Sangai 1 , Kurt W. Evans 2 , Farrell Adkins 1 , Agda Karina Eterovic 3 , Hao Zhao 4 , Ken Chen 4 , Huiqin Chen 5 , Kim-Anh Do 5 , Shelly M. Xie 1 , Ashley M. Holder 1 , Aung Naing 2 , Gordon B. Mills 3 and Funda Meric-Bernstam 1,2 1 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 2 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 3 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 4 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 5 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX Correspondence: Funda Meric-Bernstam, email: // Keywords : mTOR, Akt, rapamycin, everolimus, breast cancer Received : June 10, 2014 Accepted : August 09, 2014 Published : August 10, 2014 Abstract We tested the antitumor efficacy of mTOR catalytic site inhibitor MLN0128 in models with intrinsic or acquired rapamycin-resistance. Cell lines that were intrinsically rapamycin-resistant as well as those that were intrinsically rapamycin-sensitive were sensitive to MLN0128 in vitro . MLN0128 inhibited both mTORC1 and mTORC2 signaling, with more robust inhibition of downstream 4E-BP1 phosphorylation and cap-dependent translation compared to rapamycin in vitro . Rapamycin-sensitive BT474 cell line acquired rapamycin resistance (BT474 RR) with prolonged rapamycin treatment in vitro . This cell line acquired an mTOR mutation (S2035F) in the FKBP12-rapamycin binding domain; mTORC1 signaling was not inhibited by rapalogs but was inhibited by MLN0128. In BT474 RR cells, MLN0128 had significantly higher growth inhibition compared to rapamycin in vitro and in vivo . Our results demonstrate that MLN0128 may be effective in tumors with intrinsic as well as acquired rapalog resistance. mTOR mutations are a mechanism of acquired resistance in vitro ; the clinical relevance of this observation needs to be further evaluated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2337

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 61

Metadata

Authors
Hassan, B., Akcakanat, A., Sangai, T., Evans, K. W., Adkins, F., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., Xie, S. M., Holder, A. M., Naing, A., Mills, G. B., & Meric-Bernstam, F.
Venue
Oncotarget
Published
2014-08-10
Volume
5
Issue
18
Pages
8544-8557
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2119607485
Cited by
61
References
12
FWCI
2.92
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.